SeaCrest Wealth Management’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $664K | Sell |
3,504
-3,456
| -50% | -$650K | 0.07% | 235 |
|
|
2026
Q1 | $1.37M | Sell |
6,960
-80
| -1% | -$15.4K | 0.15% | 129 |
|
|
2025
Q4 | $1.34M | Sell |
7,040
-158
| -2% | -$27.7K | 0.14% | 139 |
|
|
2025
Q3 | $1.23M | Sell |
7,198
-575
| -7% | -$87K | 0.13% | 151 |
|
|
2025
Q2 | $1.09M | Sell |
7,773
-249
| -3% | -$34.9K | 0.12% | 168 |
|
|
2025
Q1 | $1.18M | Sell |
8,022
-179
| -2% | -$25.9K | 0.13% | 151 |
|
|
2024
Q4 | $1.07M | Sell |
8,201
-472
| -5% | -$66.1K | 0.11% | 167 |
|
|
2024
Q3 | $1.35M | Sell |
8,673
-84
| -1% | -$13.6K | 0.15% | 135 |
|
|
2024
Q2 | $1.37M | Buy |
8,757
+80
| +0.9% | +$12K | 0.16% | 126 |
|
|
2024
Q1 | $1.18M | Buy |
8,677
+210
| +2% | +$27.8K | 0.14% | 153 |
|
|
2023
Q4 | $1.16M | Buy |
8,467
+473
| +6% | +$61.5K | 0.14% | 144 |
|
|
2023
Q3 | $1.08M | Sell |
7,994
-122
| -2% | -$16.7K | 0.14% | 154 |
|
|
2023
Q2 | $1.16M | Sell |
8,116
-251
| -3% | -$36.9K | 0.15% | 145 |
|
|
2023
Q1 | $1.16M | Sell |
8,367
-136
| -2% | -$18.3K | 0.16% | 138 |
|
|
2022
Q4 | $1.15M | Sell |
8,503
-90
| -1% | -$11.3K | 0.17% | 141 |
|
|
2022
Q3 | $942K | Buy |
8,593
+233
| +3% | +$29.6K | 0.14% | 154 |
|
|
2022
Q2 | $1.1M | Buy |
8,360
+369
| +5% | +$48.4K | 0.14% | 152 |
|
|
2022
Q1 | $1.06M | Buy |
7,991
+957
| +14% | +$115K | 0.12% | 182 |
|
|
2021
Q4 | $819K | Buy |
7,034
+210
| +3% | +$24.7K | 0.09% | 222 |
|
|
2021
Q3 | $820K | Buy |
6,824
+523
| +8% | +$60.9K | 0.1% | 217 |
|
|
2021
Q2 | $755K | Sell |
6,301
-140
| -2% | -$15.4K | 0.09% | 241 |
|
|
2021
Q1 | $640K | Sell |
6,441
-109
| -2% | -$11K | 0.08% | 255 |
|
|
2020
Q4 | $655K | Sell |
6,550
-5,800
| -47% | -$614K | 0.09% | 237 |
|
|
2020
Q3 | $1.35M | Buy |
12,350
+4,695
| +61% | +$522K | 0.22% | 98 |
|
|
2020
Q2 | $810K | Buy |
7,655
+2,180
| +40% | +$225K | 0.14% | 166 |
|
|
2020
Q1 | $489K | Sell |
5,475
-110
| -2% | -$10.4K | 0.11% | 214 |
|
|
2019
Q4 | $557K | Sell |
5,585
-54
| -1% | -$5.08K | 0.09% | 250 |
|
|
2019
Q3 | $503K | Sell |
5,639
-132
| -2% | -$11.4K | 0.09% | 260 |
|
|
2019
Q2 | $476K | Sell |
5,771
-257
| -4% | -$20.2K | 0.1% | 252 |
|
|
2019
Q1 | $487K | Sell |
6,028
-220
| -4% | -$17.3K | 0.08% | 239 |
|
|
2018
Q4 | $475K | Buy |
6,248
+154
| +3% | +$12K | 0.1% | 212 |
|
|
2018
Q3 | $482K | Buy |
6,094
+138
| +2% | +$10.4K | 0.08% | 263 |
|
|
2018
Q2 | $418K | Buy |
5,956
+88
| +1% | +$6.33K | 0.08% | 291 |
|
|
2018
Q1 | $410K | Sell |
5,868
-98
| -2% | -$6.79K | 0.08% | 290 |
|
|
2017
Q4 | $414K | Buy |
+5,966
| New | +$402K | 0.08% | 286 |
|
Other funds holding AZN
EP
IA
SeaCrest Wealth Management's AZN Position: Q2 2026 in Review
SeaCrest Wealth Management reduced its AstraZeneca (AZN) stake by 50% in Q2 2026, selling an estimated $650K and leaving 3,504 shares worth $664K. The position accounts for 0.07% of the portfolio, ranked #235.
SeaCrest Wealth Management first reported a position in AZN in Q4 2017 and has held it in 35 quarters since. The position peaked at $1.37M in Q1 2026. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- SeaCrest Wealth Management held 3,504 shares of AstraZeneca worth $664K as of Q2 2026.
- SeaCrest Wealth Management sold 3,456 AstraZeneca shares in Q2 2026, an estimated $650K.
- AstraZeneca made up 0.07% of SeaCrest Wealth Management's portfolio in Q2 2026, its #235 holding.
- SeaCrest Wealth Management first reported a position in AstraZeneca in Q4 2017 and has held it in 35 quarters since.
- SeaCrest Wealth Management's AstraZeneca position peaked at $1.37M in Q1 2026.
- 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on SeaCrest Wealth Management's 13F filing for Q2 2026, filed 9 Jul 2026.